CATALYSTYahoo Finance • 2d ago
vTv Therapeutics stock jumps on FDA orphan drug statusYahoo Finance report covering vTv Therapeutics Inc. (Class A) (VTVT) market action, institutional positioning, and fundamental catalysts.
Why VTVT Stock dropped -2.48% Today — RQD Quant Desk Flash
$23.55 -2.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $23.40
vTv Therapeutics Inc. (Class A) (VTVT) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $95.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on VTVT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is VTVT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, vTv Therapeutics Inc. (Class A) (NASDAQ: VTVT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $23.55 (-2.48% 1D, market cap $95.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, VTVT ranks #941 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does VTVT compare to NRXP and ORGO in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VTVT carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NRXP (NRX Pharmaceuticals Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $94.0M) and ORGO (Organogenesis Holdings Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC 17.1%, cap $97.2M). Among the 5-stock peer group, VTVT leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for VTVT?
▼
Per VTVT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001641489), vTv Therapeutics Inc. (Class A) generated $91.9M in revenue (+8932.7% YoY), -$27.0M in net income, and -$25.3M in free cash flow against $89.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
🎯 VTVT TRADE EXECUTION LEVELS + TODAY'S TOP 3 TRADES
EXACT ENTRY • HARD STOP-LOSS (SUP) • TARGET (RES) • WHY
Where to Enter $VTVT, Where to Set Your Hard Stop-Loss & Today's Top 3 High-Conviction Trades
🏆 RECENT ALERT WINNERS:
$XYZ +15.6% (2d)
$PLTR +13.7% (4d)
$VRT +8.4% (2d)
CURRENT TICKER SETUP • $VTVT
R/R 2.2 : 1 • RQD 24/100 (E)
$VTVT
Spot $23.55 1. GET IN (ENTRY)
$23.41–$23.67
2. HARD STOP (SUP)
$22.33 (-5.2%)
3. GET OUT (T1/T2)
$25.08 / $26.26
STOP-LOSS FLOOR (SUP $22.33):
Hard stop sits 5.2% below spot to cap downside below key institutional support. If $VTVT closes a daily candle below $22.33, step aside.
PROFIT TARGETS (RES $25.08 / $26.26):
Scale out 50% at T1 (+6.5%) and trail stop to breakeven for T2 (+11.5%).
Want this $VTVT sheet + Today's Top 3 Trades emailed free?
Paper Trade $VTVT →
⚡ TODAY'S TOP 3 SUGGESTED TRADES OF THE DAY (100% FREE CHEAT SHEET)
Trade #1 Unlocked • Enter Email Below to Unblur #2 & #3 + Get $VTVT Sheet
#1 • $MU R/R 3.2 : 1
Micron Technology, Inc.
IN
$108.50
STOP
$103.90
OUT
$117.50
#2 • 🔒 LOCKED R/R 3.4 : 1
AI Liquid-Cooling Leader
Target: +8.53% to +14.86%
| Stop: -3.89%
#3 • 🔒 LOCKED R/R 3.1 : 1
Cash-Flow Buyback Machine
Target: +8.38% to +14.53%
| Stop: -3.93%
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $23.40 (-0.64%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-15.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VTVT)Realized 20D OHLCV Swing Band: ±11%
Deterministic 5-Pillar Attribution (24/100 Composite)
🔍 WHY VTVT SCORES 24/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (29% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (25% of score)
FRED Regime × Technicals: 14% of 52W Range • RSI-14 at 29.1 (OVERSOLD (<32))
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$28.23-1.4% Next Q
32
Q2 (-2Q)Grade E$27.84-7.6% Next Q
29
Q3 (-1Q)Grade E$25.72-8.4% Next Q
27
CurrentGrade E$23.55-10.9% Hist 90D α
24
Trajectory: E (32) → E (24)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a VTVT Turnaround Squeeze
While VTVT currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($29.93) and Max Pain ($24.73) forces dealer call-delta covering toward $46.20.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $VTVT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VTVT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why VTVT Stock dropped -2.48% Today — RQD Quant Desk Flash
vTv Therapeutics Inc. (Class A) (VTVT) dropped -2.48% to $23.55, trading at 14% of its 52-week range ($20.23 – $44). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 14% of its 52-week range ($20.23 – $44) with RSI-14 at 29.1 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11% around $23.55 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live VTVT Headlines & Catalysts
MARKET WIRESimply Wall St • 2d ago
vTv Therapeutics (Nasdaq:VTVT) - Stock AnalysisSimply Wall St report covering vTv Therapeutics Inc. (Class A) (VTVT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 2d ago
vTv Therapeutics (NASDAQ:VTVT) Given "Buy" Rating at BTIG ResearchMarketBeat report covering vTv Therapeutics Inc. (Class A) (VTVT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 2d ago
An estimated 2.1 million Americans live with type 1 diabetes. A trial tests an added pill with automated insulin systems.Stock Titan report covering vTv Therapeutics Inc. (Class A) (VTVT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 2d ago
vTv Therapeutics (NASDAQ:VTVT) Stock Bumped Down to Sell by Wall Street ZenMarketBeat report covering vTv Therapeutics Inc. (Class A) (VTVT) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.dars.gov.et/ • 2d ago
vTv Therapeutics Stock Falls 3.81% to $26.54, Approaching Key Support at $25.21 - Dividend ETFhttps://www.dars.gov.et/ report covering vTv Therapeutics Inc. (Class A) (VTVT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 3d ago
vTv Therapeutics Inc. (NASDAQ:VTVT) Stock Has Consensus Price Target of $55.83MarketBeat report covering vTv Therapeutics Inc. (Class A) (VTVT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 3d ago
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Rating of "Moderate Buy" from BrokeragesMarketBeat report covering vTv Therapeutics Inc. (Class A) (VTVT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 8d ago
vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery SystemsPhase 2a pilot study aims to inform the design and conduct of future Phase 3 research in this population Cadisegliatin is a potential first-in-class oral therapy being evaluated as an adjunct to insulin for the treatment
MARKET WIREBenzinga • 8d ago
vTv Therapeutics Announces First Patient Randomized In Phase 2a Hybrid CATT1 Study Of Cadisegliatin In Type 1 DiabetesPhase 2a pilot study aims to inform the design and conduct of future Phase 3 research in this populationCadisegliatin is a potential first-in-class oral therapy being evaluated as an adjunct to insulin for the treatment
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VTVT)
- ✓Walkthrough of VTVT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
VTVT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.94%▼ SUPPORT BREAKDOWN
2026-11-04O $25.17H $25.17L $23.55C $23.55VOL 20.8K
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
VTVT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +8932.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on VTVT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for VTVT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VTVT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VTVT)
Health Care Rank #941 of 1015
⚔️ NRXP vs VTVT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (VTVT vs. NRXP, ORGO, UNCY, NTHI)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, vTv Therapeutics Inc. (Class A) (VTVT) ranks #941 by composite RQD confidence (24/100, grade E) and #659 by equity capitalization ($95.5M). Within this direct 5-issuer industry benchmark cohort, VTVT leads on earnings valuation at N/A trailing P/E, while ORGO leads on capital efficiency and profitability with 17.1% ROIC and — gross margin. ORGO currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with VTVT at 24/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VTVT
ACTIVE
vTv Therapeutics Inc. (Class A) | E | 24/100 | — | — | -35.0% | -2.48% | $95.5M | Benchmark Subject |
| NRXP NRX Pharmaceuticals Inc. | E | 25/100 | — | 58.8% | -35.0% | +3.23% | $94.0M | /nrxp-vs-vtvt → |
| ORGO Organogenesis Holdings Inc. (Class A) | E | 34/100 | — | — | 17.1% | +10.52% | $97.2M | /orgo-vs-vtvt → |
| UNCY Unicycive Therapeutics Inc. | E | 31/100 | — | — | -35.0% | +2.87% | $97.2M | /uncy-vs-vtvt → |
| NTHI NeOnc Technologies Holdings Inc. | E | 31/100 | — | — | -35.0% | 0.00% | $91.4M | /nthi-vs-vtvt → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001641489 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), vTv Therapeutics Inc. (Class A) (VTVT) reported GAAP revenue of $91.9M (+8932.7% vs. FY2024 revenue of $1.0M , and +28.6% cumulative change since FY2023) , GAAP net income of -$27.0M, operating cash flow of -$25.3M, and free cash flow of -$25.3M (+0.2% YoY). On the balance sheet, VTVT closed FY2025 with $89.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $91.9M | -$27.0M | -$25.3M | -$25.3M | $89.9M | — |
| FY2024 (FY) | 2024-12-31 | $1.0M | -$18.5M | -$25.3M | -$25.3M | $38.3M | — |
| FY2023 (FY) | 2023-12-31 | $71.4M | -$20.3M | -$19.1M | -$19.1M | — | — |
3. VTVT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs VTVT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, vTv Therapeutics Inc. (Class A) (NASDAQ: VTVT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $23.55 (-2.48% 1D, market cap $95.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, VTVT ranks #941 in composite RQD confidence.
How does VTVT compare to NRXP and ORGO in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VTVT carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NRXP (NRX Pharmaceuticals Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $94.0M) and ORGO (Organogenesis Holdings Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC 17.1%, cap $97.2M). Among the 5-stock peer group, VTVT leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for VTVT?
Per VTVT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001641489), vTv Therapeutics Inc. (Class A) generated $91.9M in revenue (+8932.7% YoY), -$27.0M in net income, and -$25.3M in free cash flow against $89.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is VTVT trading relative to its 50-day, 200-day, and 52-week technical levels?
VTVT last traded at $23.55 (-2.48% on volume of 37,933 shares), positioning the stock -21.32% below its 50-day simple moving average ($29.93) and -29.47% below its 200-day simple moving average ($33.39). Across its 52-week range of $20.23 to $44.00, VTVT sits at the 14.0% percentile with a 14-day RSI of 29.1 (OVERSOLD (<32)) and an implied next-earnings move of ±11.0% ($20.96 to $26.14).
ROARABLE RATING BRIEF • RQD 24/100 (E)
✓ SEC XBRL & RQD VERIFIED
VTVT — vTv Therapeutics Inc. (Class A): What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
vTv Therapeutics Inc. (Class A) (VTVT) earns a live Roarable RQD composite score of 24/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $23.55 (-2.48% 1D, market capitalization $95.5M).
- Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -24.21%.
- Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (6/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
VTv Therapeutics Inc. (Class A) (VTVT) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The FY 2025 and FY 2024 financials show revenue of — and $1.0M respectively, with operating losses in each period ().
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), vTv Therapeutics Inc. (Class A) (VTVT) reported $91.9M in annual revenue (up from $1.0M in FY2024, +8932.7% YoY) and -$27.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($71.4M revenue, -$20.3M net income) through FY2025, VTVT scaled operating cash flow to -$25.3M and free cash flow to -$25.3M, backed by $89.9M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 24/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -24.21% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $20.23 – $44.00 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from source data. A prospective investor should note that the absence of mapped links means no verified ripple effects can be drawn from this dataset.
- Key Question #1: Can VTVT sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $91.9M and free cash flow of -$25.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is VTVT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
VTVT Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for vTv Therapeutics Inc. (Class A) (VTVT) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 2d ago
vTv Therapeutics stock jumps on FDA orphan drug status Yahoo Finance report covering vTv Therapeutics Inc. (Class A) (VTVT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 2d ago
vTv Therapeutics (Nasdaq:VTVT) - Stock Analysis Simply Wall St report covering vTv Therapeutics Inc. (Class A) (VTVT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 2d ago
vTv Therapeutics (NASDAQ:VTVT) Given "Buy" Rating at BTIG Research MarketBeat report covering vTv Therapeutics Inc. (Class A) (VTVT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 2d ago
An estimated 2.1 million Americans live with type 1 diabetes. A trial tests an added pill with automated insulin systems. Stock Titan report covering vTv Therapeutics Inc. (Class A) (VTVT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 2d ago
vTv Therapeutics (NASDAQ:VTVT) Stock Bumped Down to Sell by Wall Street Zen MarketBeat report covering vTv Therapeutics Inc. (Class A) (VTVT) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.dars.gov.et/ • 2d ago
vTv Therapeutics Stock Falls 3.81% to $26.54, Approaching Key Support at $25.21 - Dividend ETF https://www.dars.gov.et/ report covering vTv Therapeutics Inc. (Class A) (VTVT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 3d ago
vTv Therapeutics Inc. (NASDAQ:VTVT) Stock Has Consensus Price Target of $55.83 MarketBeat report covering vTv Therapeutics Inc. (Class A) (VTVT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 3d ago
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Rating of "Moderate Buy" from Brokerages MarketBeat report covering vTv Therapeutics Inc. (Class A) (VTVT) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
VTVT Bull vs. Bear Conversation Board — What's Your Call at $23.55?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VTVT 🐻 33% BEARISH CONVICTION
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH
🎯 Target: $30.46 (+21.0%)
📌 Pinned Debate The stock jumped on an FDA orphan drug status report, and its $88.9M cash balance in FY 2025 rose sharply from $36.7M the prior year.
The stock jumped on an FDA orphan drug status report, and its $88.9M cash balance in FY 2025 rose sharply from $36.7M the prior year.. When you look under the hood at VTVT, Fundamental Cash Engine is 5/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $44.00. My 12M target is $30.46.
RetailWhale_TX 🐂 BULL
Both sides have a point here — VTVT's 7/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH
🎯 Target: $21.39 (-15.0%)
Spot @ $25.17 A -35% ROIC, -24.21% FCF yield, 0.2 Altman Z-Score, and 2/9 Piotroski F-Score signal cash burn and high forensic distress risk.
Fading this rally in VTVT at $25.17. A -35% ROIC, -24.21% FCF yield, 0.2 Altman Z-Score, and 2/9 Piotroski F-Score signal cash burn and high forensic distress risk.. With a beta of 1.0 and the stock sitting at $25.17 (52-wk range $20.04–$44.00), the easy multiple expansion is already priced in.